- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| XUANZHU BIOPHARMACEUTICAL Aktie jetzt für 0€ handeln | |||||
| 13.08. | XUANZHUBIO-B (02575): DATE OF BOARD MEETING | - | HKEx | ||
| 30.06. | XUANZHUBIO-B (02575): VOLUNTARY ANNOUNCEMENT NDA ACCEPTED BY NMPA FOR THE NEW INDICATION OF ANAPRAZOLE SODIUM FOR THE TREATMENT OF REFLUX ESOPHAGITIS | 3 | HKEx | ||
| 18.06. | XUANZHUBIO-B (02575): LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION | - | HKEx | ||
| 18.06. | XUANZHUBIO-B (02575): ELECTION OF EMPLOYEE REPRESENTATIVE DIRECTOR | 1 | HKEx | ||
| 18.06. | XUANZHUBIO-B (02575): ARTICLES OF ASSOCIATION | 1 | HKEx | ||
| 18.06. | XUANZHUBIO-B (02575): POLL RESULTS OF THE 2025 ANNUAL GENERAL MEETING AND ABOLISHMENT OF THE SUPERVISORY COMMITTEE AND AMENDMENTS TO THE ARTICLES OF ASSOCIATION | - | HKEx | ||
| 27.05. | XUANZHUBIO-B (02575): FORM OF PROXY FOR THE ANNUAL GENERAL MEETING | 3 | HKEx | ||
| 27.05. | XUANZHUBIO-B (02575): NOTICE OF THE 2025 ANNUAL GENERAL MEETING | 1 | HKEx | ||
| 27.05. | XUANZHUBIO-B (02575): CIRCULAR FOR THE 2025 ANNUAL GENERAL MEETING | 1 | HKEx | ||
| 26.05. | XUANZHUBIO-B (02575): PROPOSED AMENDMENT TO THE ARTICLES OF ASSOCIATION, ABOLITION OF THE SUPERVISORY COMMITTEE AND CHANGE OF BOARD COMPOSITION | - | HKEx | ||
| 12.05. | XUANZHUBIO-B (02575): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 12.05. | XUANZHUBIO-B (02575): INSIDE INFORMATION COMPLETION OF THE H SHARE FULL CIRCULATION BY THE COMPANY | 1 | HKEx | ||
| 27.04. | XUANZHUBIO-B (02575): LETTER TO NON-REGISTERED SHAREHOLDERS - REMINDER LETTER REGARDING THE ARRANGEMENT OF ELECTRONIC DISSEMINATION OF CORPORATE COMMUNICATIONS ... | 2 | HKEx | ||
| 27.04. | XUANZHUBIO-B (02575): LETTER TO REGISTERED SHAREHOLDERS - REMINDER LETTER REGARDING THE ARRANGEMENT OF ELECTRONIC DISSEMINATION OF CORPORATE COMMUNICATIONS ... | 1 | HKEx | ||
| 27.04. | XUANZHUBIO-B (02575): 2025 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | - | HKEx | ||
| 27.04. | XUANZHUBIO-B (02575): 2025 ANNUAL REPORT | 1 | HKEx | ||
| 20.04. | XUANZHUBIO-B (02575): VOLUNTARY ANNOUNCEMENT RESULTS OF PRELIMINARY DATA FROM THE PHASE 1B FORTRESS CLINICAL STUDY OF NG-350A PRESENTED AT THE 2026 AACR | - | HKEx | ||
| 17.04. | XUANZHUBIO-B (02575): INSIDE INFORMATION APPROVAL BY THE STOCK EXCHANGE REGARDING THE APPLICATION FOR THE PROPOSED IMPLEMENTATION OF H SHARE FULL CIRCULATION | 1 | HKEx | ||
| 15.04. | XUANZHUBIO-B (02575): VOLUNTARY ANNOUNCEMENT APPROVAL TO INITIATE A PHASE III CLINICAL TRIAL FOR NEW INDICATION OF ANAPRAZOLE SODIUM | 1 | HKEx | ||
| 09.04. | XUANZHUBIO-B (02575): VOLUNTARY ANNOUNCEMENT - LICENSING AND SUPPLY AGREEMENT WITH BOSTON ONCOLOGY FOR BIREOCICLIB AND DIROZALKIB | 1 | HKEx |
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AMYLYX PHARMACEUTICALS | 38,660 | 0,00 % | Kaum zu fassen: Die unglaubliche Biotech-Story von Amylyx Pharmaceuticals | Der Biotech-Sektor ist immer wieder für faustdicke Überraschungen gut - sowohl negativ als auch positiv. Bei Amylyx Pharmaceuticals gibt es am Dienstag keine zwei Meinungen: Die Aktie des Biotech-Unternehmens... ► Artikel lesen | |
| BEAM THERAPEUTICS | 29,760 | 0,00 % | Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD) | Updated BEAM-302 Phase 1/2 Clinical Data Selected for Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026 Dosing Complete for All Adult and Adolescent Patients... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 375,86 | 0,00 % | Raymond James raises Praxis Precision Medicines price target on pipeline outlook | ||
| APOGEE THERAPEUTICS | 134,73 | -0,01 % | AbbVie schließt Anleiheemission über 8,0 Mrd. US-Dollar zur Finanzierung der Übernahme von Apogee Therapeutics ab | ||
| SUMMIT THERAPEUTICS | 13,150 | 0,00 % | Could Arcus Biosciences (RCUS) and Summit Therapeutics (SMMT)'s Cancer Drug Partnership Create a New Treatment Standard? | ||
| COGENT BIOSCIENCES | 36,710 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 59,94 | +0,19 % | Barclays startet Coverage für Enliven Therapeutics mit "Overweight" und Kursziel von 78 Dollar | ||
| MONTE ROSA THERAPEUTICS | 14,300 | 0,00 % | Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates | Positive interim Phase 1 data of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in elevated CVD-risk subjects; readout of expanded part 3 CRP PoC trial (now called GFORCE-1) anticipated... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 119,91 | +0,09 % | Kymera International Appoints Willson Ropp as Chief Executive Officer | Experienced specialty materials executive brings more than 30 years of leadership experience across global manufacturing, operational excellence, business integration, and long-term value... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 38,150 | 0,00 % | Harmony Biosciences Announces Record Q2 2026 Revenue and Shares Initial Clinical Data for Its Orexin-2 Agonist BP-205 Reinforcing Potential Best-in-Class Profile | WAKIX® Net Revenue Grew 30% Year over Year to $261.3 Million for Second Quarter 2026; Estimated Average Patients Increased 450 to 8,950; Reiterates 2026 WAKIX Net Revenue Guidance of $1.0 Billion... ► Artikel lesen | |
| RELAY THERAPEUTICS | 19,440 | 0,00 % | H.C. Wainwright raises Relay Therapeutics price target to $29 | ||
| TANGO THERAPEUTICS | 23,900 | +0,08 % | H.C. Wainwright hebt Kursziel für Tango Therapeutics auf 68 US-Dollar an | ||
| ARCTURUS THERAPEUTICS | 13,440 | -0,07 % | Arcturus auf der 46. Jährlich Wachstumskonferenz von Canaccord Genuity: Starke Liquidität und bevorstehende Katalysatoren | ||
| ARCUTIS BIOTHERAPEUTICS | 25,100 | +0,08 % | Arcutis Biotherapeutics, Inc.: Arcutis Expands Board of Directors with Appointment of Chris Peetz | WESTLAKE VILLAGE, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovation in... ► Artikel lesen | |
| VERA THERAPEUTICS | 32,280 | 0,00 % | Weekly Buzz: Johnson & Johnson, Vera Therapeutics Get FDA Nod; Vertex Pharmaceuticals Snaps Up Crinetics Pharmaceuticals; Satellos Bioscience Aces DMD Trial; Ionis Pharmaceuticals Misses Key Goal | NEW BRUNSWICK (dpa-AFX) - This week featured a steady stream of regulatory milestones, strategic dealmaking, and pivotal clinical trial updates, alongside missed trial goals across the biotech... ► Artikel lesen |
XUANZHU BIOPHARMACEUTICAL CO LTD gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -3,31 % bei einem Aktienkurs von 1,110 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu XUANZHU BIOPHARMACEUTICAL CO LTD finden Sie auf Wallstreet Online.